We are live on ! Find out more
AXLA

Axcella Health Inc. Common Stock

Delisted

AXLA was delisted on the 22nd of November, 2023.

32 hedge funds and large institutions have $58.6M invested in Axcella Health Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 16 increasing their positions, 1 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,500% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 1

43% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 7

10% more funds holding

Funds holding: 2932 (+3)

0% more funds holding in top 10

Funds holding in top 10: 22 (0)

28% less capital invested

Capital invested by funds: $81.1M → $58.6M (-$22.5M)

Holders
32
Holders Change
+3
Holders Change %
+10.34%
% of All Funds
0.63%
Holding in Top 10
2
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.04%
New
10
Increased
16
Reduced
1
Closed
7
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$35.1M
Fidelity Investments
2
Fidelity Investments
Massachusetts
$12.9M -$968K -8,811 -6%
HP
3
Harbourvest Partners
Massachusetts
$4.93M
AG
4
Artal Group
Luxembourg
$1.8M
BlackRock
5
BlackRock
New York
$1.2M +$953K +8,673 +267%
Vanguard Group
6
Vanguard Group
Pennsylvania
$774K +$88.1K +802 +12%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$306K +$1.32K +12 +0.4%
CIC
8
Chilton Investment Company
Connecticut
$263K +$90.1K +820 +46%
State Street
9
State Street
Massachusetts
$230K +$252K +2,290 New
Northern Trust
10
Northern Trust
Illinois
$178K +$65.5K +596 +51%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$155K +$171K +1,556 New
PCM
12
Pinz Capital Management
New York
$137K +$150K +1,365 New
JP Morgan Chase
13
JP Morgan Chase
New York
$126K +$135K +1,232 +5,867%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$80K +$87.4K +795 New
UBS Group
15
UBS Group
Switzerland
$76K +$77.3K +703 +1,172%
Charles Schwab
16
Charles Schwab
California
$69K +$74.7K +680 New
Jacobs Levy Equity Management
17
Jacobs Levy Equity Management
New Jersey
$59K +$65.1K +592 New
N
18
Nuveen
North Carolina
$51K +$56.4K +513 New
California State Teachers Retirement System (CalSTRS)
19
California State Teachers Retirement System (CalSTRS)
California
$48K +$41.3K +376 +372%
New York State Common Retirement Fund
20
New York State Common Retirement Fund
New York
$44K
Morgan Stanley
21
Morgan Stanley
New York
$42K +$43.6K +397 +1,890%
Barclays
22
Barclays
United Kingdom
$31K +$27.9K +254 +438%
AIG
23
American International Group
New York
$20K +$16.9K +154 +376%
Bank of America
24
Bank of America
North Carolina
$10K +$2.64K +24 +34%
Deutsche Bank
25
Deutsche Bank
Germany
$10K +$9.67K +88 +518%

AXLA Hedge Fund Activity: Q4 2019 in Review

32 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Axcella Health Inc. Common Stock (AXLA) for Q4 2019, worth a combined $58.6M — down 28% from $81.1M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new AXLA positions and 7 closed out — a net gain of 3 holders — while 16 added to existing stakes and 1 trimmed.

The largest buyer was BlackRock, adding an estimated $953K. The largest seller was Fidelity Investments, cutting an estimated $968K.

  • 32 institutional investors held Axcella Health Inc. Common Stock (AXLA) as of Q4 2019, up from 29 in Q3 2019.
  • Funds reported $58.6M of Axcella Health Inc. Common Stock stock for Q4 2019, down 28% quarter-over-quarter.
  • 10 funds opened new Axcella Health Inc. Common Stock positions in Q4 2019 and 7 closed out, a net change of +3 holders.
  • The largest Axcella Health Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $953K added.
  • The largest Axcella Health Inc. Common Stock seller in Q4 2019 was Fidelity Investments, an estimated $968K sold.

Based on aggregated 13F filings for Q4 2019.